Browse Studies — Arctuva

Phase 2

A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the lab…

Advanced Non-Small Cell Lung CancerSquamous Cell CarcinomaAdvanced NSCLC+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT02133196

Phase 1

A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications

This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination t…

Advanced Solid TumorNon Small Cell Lung CancerUntreated Advanced NSCLC+1 more

Estimated

~$10 – $7,500

SynthekineNCT05098132

Phase 2

Olomorasib Plus Pembrolizumab as First-Line Treatment for KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell…

Lung CancerLung Cancer (NSCLC)Locally Advanced NSCLC+1 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07639242

Phase 2

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzu…

Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more

Estimated

~$10 – $7,500

Jun Zhang, MD, PhDNCT05859217